Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
CD Protein Inhibitors
>>
Phase 1
«
1
2
3
4
5
6
7
8
9
10
11
12
13
»
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
1
2
3
4
5
6
7
8
9
10
SIM0237
/ Simcere
SSGJ-705
/ 3SBio
STSA-1005
/ Staidson Biopharma
TG-1801
/ Light Chain Biosci, TG Therap
TRS005
/ Zhejiang Teruisi Biopharma
ThisCART22
/ Fundamenta Therap
XmAb968
/ Xencor
Y150
/ YZY Biopharma
YH004
/ Biocytogen
anti-CD19 CAR-T cell therapy
/ Bioceltech
anti-CD19/BCMA CAR-T cells
/ Hrain Biotech
anti-CD22 CAR T
/ National Cancer Institute
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
/ National Cancer Institute
autologous CD7-CAR T cells
/ Beijing Boren Hospital
azercabtagene zapreleucel
(PBCAR0191) / Imugene, TG Therap
betifisolimab
(MSB2311) / Transcenta
davoceticept
(ALPN-202) / Alpine Immune Sci
denocabtagene ciloleucel
(CAR-T-19-DNR) / Immunotech Biopharm
duvortuxizumab
(MGD011) / MacroGenics
eluvixtamab
(AMG 330) / Amgen
eramkafusp alfa
(IGN002) / Assertio
gentulizumab
/ GeneScience
human anti CD19 CAR-T cells
/ Case Comprehensive Cancer Center
imaprelimab
(PRX003) / Prothena
opucolimab
(HLX20) / Fosun Pharma
orlotamab
(MGD009) / MacroGenics
pacanalotamab
(AMG 420) / Amgen
rezetamig
(JNJ-8780) / J&J
sequential different B cell antigen-targeted CAR T-cell therapy
/ Beijing Boren Hospital
vorsetuzumab mafodotin
(SGN-75) / Pfizer
welgenaleucel
(UWC19) / UWELL Biopharma
131-I Apamistamab/CAR T-cell
(Iomab-ACT) / Actinium
9MW1111
/ Mabwell (Shanghai) Biosci
AB-101
/ Arbutus
AB-1015
/ ArsenalBio
AB248
/ Asher Biotherap
AB598
/ Arcus Biosci
ABBV-184
/ AbbVie
ABBV-319
/ AbbVie
ABBV-428
/ AbbVie
ABL103
/ ABL Bio
ABL501
/ ABL Bio
ABSK043
/ Abbisko
ACE1831
/ Acepodia
ADG206
/ Adagene
AFM28
/ Affimed
AFNT-111
/ Affini-T Therap, Erasca
AGEN1571
/ Agenus
AGEN2373
/ Agenus, Gilead
AK129
/ Akesobio
«
1
2
3
4
5
6
7
8
9
10
11
12
13
»
